Patents by Inventor Agnes Taillardat

Agnes Taillardat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110189286
    Abstract: The present invention provides gastroretentive pulsatile pharmaceutical delivery systems that improve the bioavailability of Valsartan wherein the medicament has improved solubility, improved residence time in the gastrointestinal tract and a pulsatile release profile.
    Type: Application
    Filed: June 1, 2009
    Publication date: August 4, 2011
    Inventors: Amol Singh Matharu, Agnes Taillardat
  • Publication number: 20110028526
    Abstract: The invention relates to melt granulation processes for preparing immediate release and sustained release pharmaceutical formulations comprising valsartan.
    Type: Application
    Filed: February 27, 2009
    Publication date: February 3, 2011
    Inventors: Amol Matharu, Agnes Taillardat, Robert F. Wagner
  • Publication number: 20100068265
    Abstract: A pharmaceutical composition in the form of a gelatin capsule comprising a pharmaceutically acceptable acid.
    Type: Application
    Filed: December 18, 2007
    Publication date: March 18, 2010
    Inventors: Isabel Ottinger, Agnes Taillardat
  • Publication number: 20100022565
    Abstract: Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.
    Type: Application
    Filed: February 29, 2008
    Publication date: January 28, 2010
    Inventors: Thomas Buhl, Elisabete Goncalves, Oskar Kalb, Lorenz Meinel, Sibylle Reidemeister, Agnes Taillardat, Leo Widler
  • Publication number: 20080213385
    Abstract: The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer.
    Type: Application
    Filed: August 8, 2006
    Publication date: September 4, 2008
    Inventors: Oskar Kalb, Isabel Ottinger, Walter Stebler, Agnes Taillardat, Wolfgang Wirth